Cargando…
Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review
BACKGROUND: Effective systemic treatment of non-clear cell renal carcinoma (nccRCC) is still an unmet clinical need, with few studies to support an evidence-based approach. To date, the only recommended standard first-line treatment is sunitinib. Pazopanib may also be used in nccRCC but its place in...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278098/ https://www.ncbi.nlm.nih.gov/pubmed/32550862 http://dx.doi.org/10.1177/1758835920915303 |